CRC | Jotup

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Retrieved on:

Wednesday, March 13, 2024

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.

Key Points:

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.
BLUE-C investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences.
This enrollment diversity helps ensure that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.
ET to discuss results of the pivotal BLUE-C study.

Compliance Risk Concepts Introduces Enterprise Risk Management Practice

Retrieved on:

Tuesday, March 12, 2024

Professional Services, Business, Legal, Finance, Fintech, Consulting, Banking, Organization, Risk management, Risk, FDIC, Liability (financial accounting), Avnet, CRC, Lung compliance, GRC, Financial institution

Compliance Risk Concepts (CRC), an enterprise risk and compliance partner for financial services organizations, has introduced a dedicated Enterprise Risk Management practice for Financial Institutions.

Key Points:

Compliance Risk Concepts (CRC), an enterprise risk and compliance partner for financial services organizations, has introduced a dedicated Enterprise Risk Management practice for Financial Institutions.
“The demand for our enterprise risk management services is expected to be exceptionally strong, driven by the anticipated regulatory shifts and heightened focus on smaller financial institutions,” said Mitch Avnet, founder and CEO of CRC.
“By conducting a thorough gap analysis, these entities can craft a clear roadmap to align their corporate governance and risk management frameworks with the FDIC’s expectations.
CRC anticipates a significant demand for this support and plans to increase its employee headcount of experienced risk and compliance professionals to meet industry needs.

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on:

Tuesday, March 12, 2024

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points:

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
, will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Retrieved on:

Thursday, April 4, 2024

Platelet transfusion, CRi, CRC, Patient, Rigel, SAN, CRH, AML, Pharmaceutical industry

"Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.

Key Points:

"Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.
"The findings from these analyses suggest that REZLIDHIA may provide an effective treatment for patients with AML following failure of venetoclax combination therapy.
"These data support REZLIDHIA's efficacy and well-characterized safety profile in patients with mIDH1 R/R AML who had previously been treated with venetoclax combination regimens," said Raul Rodriguez, Rigel's president and CEO.
Both patients with CRi at study entry achieved CR
Median time to CRc was 1.9 months (range 1-2.8).

Newmark Announces Expansion of Retail Capital Markets Team; Hires Industry Expert Conor Lalor to Lead

Retrieved on:

Thursday, March 28, 2024

Minter, RKF, Newmark Group, Sun Belt, Lead, Sale, Lalor, Senior, Capital market, CRC, Gold, ICSC, Financial services

Lalor's team will also collaborate closely with Chairman of Global Retail, Newmark Retail Services Mark Masinter and the broader Retail services team to advise clients on the latest retail trends.

Key Points:

Lalor's team will also collaborate closely with Chairman of Global Retail, Newmark Retail Services Mark Masinter and the broader Retail services team to advise clients on the latest retail trends.
The expansion of Retail Capital Markets further strengthens Newmark's cohesive retail services platform and the firm's Capital Markets business offerings.
"This is an exciting time in the retail sector, with strong fundamentals and investor interest rapidly expanding," said Lalor.
"Newmark has built a world-class retail leasing and capital markets business, and the opportunity to lead and team up with some of the industry's most renowned and respected professionals creates immeasurable value-creation opportunities for our clients, combining expert insight into retail trends with capital markets advisory.

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Retrieved on:

Wednesday, March 27, 2024

AML, Monroe Dunaway Anderson, CRC, Patient, Acute myeloid leukemia, Virus, University, United States patent law, Clinical trial, FDA, STS, Pharmaceutical industry

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,951,118 titled, "Preparation of Preliposomal Annamycin Lyophilizate" (the '118 patent') to be issued on April 9, 2024 to Moleculin and The University of Texas System Board of Regents.

Key Points:

Moleculin's novel candidate for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets) uses a unique lipid-based delivery technology.
In addition to the expected '118 patent, Moleculin has additional patent applications pending in the U.S. and in major jurisdictions worldwide.
Issuance of this patent underscores the importance and proprietary nature of the innovation that makes this next generation anthracycline possible."
Annamycin is Moleculin's next-generation anthracycline, initially expected to fulfill a significant unmet need for the 2nd line treatment of relapsed or refractory AML patients.

Tektronix unveils decode, trigger & search support for the CAN XL protocol aimed at the growing intelligent transportation network

Retrieved on:

Tuesday, March 19, 2024

Communication, Business manager, Tektronix, CAN in Automation, FD, ADAS, Data-rate units, SDV, ACK, MSO, CRC, CAN bus, XL, Television

BEAVERTON, Ore., March 19, 2024 /PRNewswire/ -- Tektronix, Inc, a leading provider in test and measurement solutions, today announced the release of the Tektronix CAN XL (Controller Area Network Extended Length) protocol decoder, enabling engineers incorporating the latest generation of CAN communications, and helping Tektronix customers compete in today's fast-changing technology landscape. With the ability to decode signals representing data packets transmitted using CAN XL frames in a CAN network, the Tektronix CAN XL protocol decoder runs on today's 4, 5, 6 Series MSO Oscilloscopes and also offers critical features such as error detection, analysis and debugging of timing and protocol headers. Tektronix is accelerating CAN XL design and debug workflows with this release, and the intuitive user interface on 4, 5, and 6 Series MSOs helps accelerate CAN XL workflows for the company's growing number of transportation customers.

Key Points:

Tektronix is accelerating CAN XL design and debug workflows with this release, and the intuitive user interface on 4, 5, and 6 Series MSOs helps accelerate CAN XL workflows for the company's growing number of transportation customers.
CAN XL is the latest innovation in the CAN (Controller Area Network) protocol family, developed and standardized by the CAN in Automation (CiA) consortium, of which Tektronix is a member.
The new standard allows mixed message types - Ethernet tunneling and traditional signal-based CAN – at faster data rates of 20 Mb/s.
The package includes the ability to trigger on CAN XL Start of Frame and End of Frame, as well as search through acquired signals to find specific CAN XL packets.

Government of Canada invests in 7,700 world-class researchers and projects across the country

Retrieved on:

Wednesday, March 13, 2024

It will support the acquisition of the state-of-the-art tools and infrastructure needed by researchers to advance their discoveries and innovations.

Key Points:

It will support the acquisition of the state-of-the-art tools and infrastructure needed by researchers to advance their discoveries and innovations.
The funding is distributed across the country through:
The Canada Research Chairs (CRC) program – awarding $191 million to 230 new and renewed chairholders at 50 institutions.
"Congratulations to top-tier researchers who will get a boost through this vital funding to take their projects to the next level.
CFI's John R. Evans Leaders Fund helps institutions attract and retain researchers and provides support for the Canada Research Chairs Program.

Bemis Donates Toilet Seats for Cancer Advocacy Event in Washington, D.C.

Retrieved on:

Wednesday, March 13, 2024

Mall, Colorectal cancer, Congress, Partnership, American Cancer Society, Research, Death, Woman, Bemis Manufacturing Company, CRC, Breast cancer, ACS, Large intestine, Marketing, National Mall

SHEBOYGAN FALLS, Wis., March 12, 2024 /PRNewswire/ -- Bemis Manufacturing Company, a leading manufacturer of toilet and bidet seats, announced its continued partnership with Fight Colorectal Cancer (Fight CRC) for Colorectal Cancer Awareness Month. For the third year in a row, Bemis has donated 100 toilet seats to support Fight CRC's Call-on Congress event in Washington, D.C.

Key Points:

SHEBOYGAN FALLS, Wis., March 12, 2024 /PRNewswire/ -- Bemis Manufacturing Company, a leading manufacturer of toilet and bidet seats, announced its continued partnership with Fight Colorectal Cancer (Fight CRC) for Colorectal Cancer Awareness Month.
For the third year in a row, Bemis has donated 100 toilet seats to support Fight CRC's Call-on Congress event in Washington, D.C.
The donated toilet seats are displayed on the National Mall as part of Fight CRC's advocacy efforts.
Each seat features an awareness fact or statistic about colorectal cancer, the second-deadliest cancer in the United States among men and women combined.

Silent cancers: here’s what you need to know when there are no obvious symptoms

Retrieved on:

Wednesday, April 3, 2024

Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.

Key Points:

Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.
While even silent cancers can sometimes be aggressive and advance rapidly, they can also remain dormant for years or even decades.
Some prostate, breast and thyroid cancers, for example, often evolve slowly without obvious symptoms or spreading beyond the original area.

The importance of early diagnosis

Whatever the cancer, it’s always important to get an early diagnosis though – and for silent cancers, this is obviously a challenge.
But such symptoms can be misinterpreted or easily dismissed, which contributes to delayed diagnosis and treatment.
Fortunately, in many countries including the UK, we have screening tests for diseases like breast or colon cancer, to increase early diagnoses.
Early diagnosis is a key factor for successful cancer treatment.

Biomarker discovery

From molecular profiling to liquid biopsy techniques (blood tests to diagnose cancer), innovative approaches are reshaping the landscape of cancer diagnosis, offering new avenues for personalised and precision medicine.
For example, I worked with a team using blood tests to identify cancers in more than 1,000 women recalled after screening for mammography.
Although there’s increasing awareness and use of this approach in Europe, it isn’t standard in the UK.

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.